Staff Profile

Qualifications

BSc (hons) Pharmacology 1991
MPhil 1999

Previous Positions

Research Technician 1993-1996
Junior Research associate 1996-2000

Memberships

BACR
PAMM

Research Interests

Pharmacology of novel drugs to treat cancer
Pharmacokinetics

Other Expertise

Analysis of drugs in biological material

Current Work

Evaluation of, novel drugs to inhibit DNA repair-mediated resistance to anticancer therapy, CDK inhibitors and novel nucleoside transport inhibitors to enhance antifolate efficacy.

Postgraduate Supervision

MRes student supervision 2004

Funding

Preclinical and pharmacodynamic studies with Novel DNA-PK inhibitors. N.J. Curtin (PI, 40%) A.H. Calvert (5%), BW Durkacz (10%), BT Golding (5%), RJ Griffin (5%), IR Hardcastle (5%), D.R. Newell (20%), H. Thomas (10%). KuDos Pharmaceuticals 06/02-05/06 £355,171

Preclinical evaluation of DNA-PK and ATM inhibitors. N.J. Curtin (PI, 40%) A.H. Calvert (5%), BW Durkacz (10%), BT Golding (5%), RJ Griffin (5%), IR Hardcastle (5%), D.R. Newell (20%), H. Thomas (10%). KuDos Pharmaceuticals 01/03-12/06 £413,088

Preclinical Evaluation of AT5438 D.R. Newell (PI = 50%) N.J. Curtin (25%), H. Thomas (25%). Astex Technology Ltd 05/03-05/04 £15,253

• Articles

  • Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, Marques FJG, Pye H, Yo EC, Islam K, Oo HZ, McClurg UL, Wilson L, Thomas H, Frame FM, Orozco-Moreno M, Bastian K, Arredondo HM, Roustan C, Gray MA, Kelly L, Tolson A, Mellor E, Hysenaj G, Goode EA, Garnham R, Duxfield A, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Bogdan D, Westaby D, Fowler G, Flohr P, Yuan W, Sharp A, de Bono J, Maitland NJ, Wisnovsky S, Bertozzi CR, Heer R, Guerrero RH, Daugaard M, Leivo J, Whitaker H, Pitteri S, Wang N, Elliott DJ, Schumann B, Munkley J. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene 2023, 42, 926–937.
  • Zaki MYW, Alhasan SF, Shukla R, McCain M, Laszczewska M, Geh D, Patman GL, Televantou D, Whitehead A, Mauricio JP, Barksby B, Gee LM, Paish HL, Leslie J, Younes R, Burt AD, Borthwick LA, Thomas H, Beale GS, Govaere O, Sia D, Anstee QM, Tiniakos D, Oakley F, Reeves HL. Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. Liver Cancer 2022, 11(6), 540-557.
  • Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, Keun HC, Vellano CP, Marszalek JR, Wedge SR. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. British Journal of Cancer 2022, 127, 937-947.
  • Miller DC, Reuillon T, Molyneux L, Blackburn T, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hardcastle I, Harnor SJ, Heptinstall A, Lochhead P, Martin MP, Martin NC, Myers S, Newell DR, Noble RA, Phillips N, Rigoreau L, Thomas H, Tucker JA, Wang L-Z, Waring MJ, Wong A-C, Wedge SR, Noble MEM, Cano C. Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. Journal of Medicinal Chemistry 2022, 65(9), 6513-6540.
  • Hunter JE, Campbell AE, Butterworth JA, Sellier H, Hannaway NL, Luli S, Floudas A, Kenneth NS, Moore AJ, Brownridge PJ, Thomas HD, Coxhead J, Taylor L, Leary P, Hasoon MSR, Knight AM, Garrett MD, Collins I, Eyers CE, Perkins ND. Mutation of the RelA(p65) Thr505 phosphosite disrupts the DNA replication stress response leading to CHK1 inhibitor resistance. Biochemical Journal 2022, 479(19), 2087-2113.
  • Chessari G, Hardcastle IR, Ahn JS, Anil B, Anscome E, Bawn RH, Bevan LD, Blackburn TJ, Buck I, Cano C, Carbain B, Castro J, Cons B, Cully SJ, St Denis J, Endicott JA, Fazal L, Golding BT, Griffin RJ, Haggerty K, Harnor S, Hearn K, Hobson S, Holvey RS, Howard S, Jennings C, Johnson CN, Lunec J, Miller DC, Newell DR, Noble MEM, Reeks J, Revill CH, Riedinger C, Tamanini E, Thomas H, Thompson NT, Vinkovic M, Wedge SR, Williams PA, Wilsher N, Zhang B, Zhao Y. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction. Journal of Medicinal Chemistry 2021, 64(7), 4071-4088.
  • Bainbridge A, Walker S, Smith J, Patterson K, Dutt D, Ng YM, Thomas HD, Wilson L, McCullough B, Jones D, Maan A, Banks P, McCracken SRC, Gaughan L, Robson CN, Coffey K. IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway. Nucleic Acids Research 2020, 48(10), 5366-5382.
  • Jones D, Wilson L, Thomas H, Gaughan L, Wade MA. The histone demethylase enzymes KDM3A and KDM4B co-operatively regulate chromatin transactions of the estrogen receptor in breast cancer. Cancers 2019, 11(8), 1122.
  • Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Lourenco LM, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR. Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy. Journal of Clinical Investigation 2019, 130, 1-14.
  • Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer 2019, 144(12), 3146-3159.
  • Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang L-Z, Wong A-C, Noble MEM, Wedge SR, Cano C. Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4. European Journal of Medicinal Chemistry 2019, 178, 530-543.
  • Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica 2019, 104(9), 1804-1811.
  • Coxon RC, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget 2017, 8, 19089-19124.
  • Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine 2017, 30(9), e3736.
  • Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
  • McCormick A, Earp E, Elliot K, Cuthbert G, O'Donnell R, Wilson BT, Sutton R, Leeson C, Thomas HD, Blair H, Fordham S, Lunec J, Allan J, Edmondson RJ. Functional characterisation of a novel ovarian cancer cell line, NUOC-1. Oncotarget 2017, 8(16), 26832-26844.
  • Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, Bacon CM, Cockell SJ, Gewurz BE, Perkins ND. The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma. Oncogene 2016, 35(26), 3476-3484.
  • Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. European Journal of Cancer 2016, 56, 69-76.
  • Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemotherapy and Pharmacology 2016, 78(6), 1269-1281.
  • Beale G, Haagensen E, Thomas H, Wang LZ, Revill C, Payne S, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer. British Journal of Cancer 2016, 115, 682-690.
  • McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T. Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself. PLoS One 2015, 10(2).
  • Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL. DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research 2015, 21(4), 925-933.
  • Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. British Journal of Cancer 2014, 110, 1977-1984.
  • Roughan JV, Coulter CA, Flecknell PA, Thomas HD, Sufka KJ. The Conditioned Place Preference Test for Assessing Welfare Consequences and Potential Refinements in a Mouse Bladder Cancer Model. PLoS One 2014, 9(8), e103362.
  • Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice. PLoS ONE 2013, 8(12), e81763.
  • Hill CR, Jamieson D, Thomas HD, Brown CDA, Boddy AV, Veal GJ. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology 2013, 85(1), 29-37.
  • Bell E, Ponthan F, Whitworth C, Thomas H, Redfern CPF. Cell Survival Signalling through PPARδ and Arachidonic Acid Metabolites in Neuroblastoma. PLoS One 2013, 8(7), e68859.
  • Jarvis IWH, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ. Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours. Biochemical Pharmacology 2012, 83(1), 69-77.
  • Hepburn AC, Veeratterapillay R, Williamson SC, El-Sherif A, Sahay N, Thomas HD, Mantilla A, Pickard RS, Robson CN, Heer R. Side Population in Human Non-Muscle Invasive Bladder Cancer Enriches for Cancer Stem Cells That Are Maintained by MAPK Signalling. PLoS One 2012, 7(11), e50690.
  • Drew Y, Mulligan EA, Vong W, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. Journal of the National Cancer Institute 2011, 103(4), 334-346.
  • Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ. The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice. Molecular Cancer Therapeutics 2011, 10(12), 2320-2329.
  • Thomas HD, Wang LZ, Roche C, Bentley J, Cheng YZ, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR. Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301. European Journal of Cancer 2011, 47(13), 2052-2059.
  • Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochemical Journal 2011, 436(3), 671–679.
  • Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ. Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α₁-Acid Glycoprotein. Journal of Medicinal Chemistry 2011, 54(6), 1847-1859.
  • Johnson N, Li YC, Walton ZE, Cheng KA, Li DA, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nature Medicine 2011, 17(7), 875-882.
  • Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemotherapy and Pharmacology 2010, 66(4), 807-812.
  • Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British Journal of Cancer 2010, 103(10), 1588-1596.
  • Issaeva N, Thomas HD, Djurenovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Research 2010, 70(15), 6268-6276.
  • Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?. Clinical Cancer Research 2009, 15(19), 6106-6112.
  • Darby S, Murphy T, Thomas H, Robson CN, Leung HY, Mathers ME, Gnanapragasam VJ. Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. British Journal of Cancer 2009, 101(11), 1891-1899.
  • Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity. Molecular Cancer Therapeutics 2009, 8(7), 1828-1837.
  • Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma. Clinical Cancer Research 2009, 15(4), 1241-1249.
  • Kyle S, Thomas HD, Mitchell J, Curtin NJ. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. British Journal of Radiology 2008, 81(Special Issue 1), S6-S11.
  • Thomas HD, Calabrese CR, Batey M, Canan S, Hostomsky Z, Kyle S, Maegley K, Newell DR, Skalitzky D, Wang L, Webber SE, Curtin NJ. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics 2007, 6(3), 945-956.
  • Armstrong J, Taylor GA, Thomas HD, Boddy AV, Redfern C, Veal GJ. Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo. British Journal of Cancer 2007, 96(11), 1675-1683.
  • Graham-Cole C, Thomas HD, Taylor GA, Newell DR, Melton R, Hesp R, Boddy AV. An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed. Cancer Chemotherapy and Pharmacology 2007, 59(2), 197-206.
  • Zhao Y, Thomas HD, Batey M, Cowell I, Richardson C, Griffin RJ, Calvert AH, Newell DR, Smith G, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Research 2006, 66(10), 5354-5362.
  • Veal GJ, Errington J, Thomas HD, Boddy AV, Lowis S. Biliary excretion of etoposide in children with cancer. Cancer Chemotherapy and Pharmacology 2006, 58(3), 415-417.
  • Bryant H, Schultz N, Thomas HD, Parker K, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035), 913-917.
  • Tikhe J, Webber S, Hostomsky Z, Maegley K, Ekkers A, Li J, Yu X, Almassy R, Kumpf R, Boritzki T, Zhang C, Calabrese C, Curtin NJ, Kyle S, Thomas HD, Wang L, Calvert AH, Golding B, Griffin RJ, Newell DR. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. Journal of Medicinal Chemistry 2004, 47(22), 5467-5481.
  • Calabrese C, Almassy R, Barton S, Batey M, Calvert AH, Canan-Koch S, Durkacz B, Hostomsky Z, Kumpf R, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford I, Skalitzky D, Thomas HD, Wang L, Webber S, William K, Curtin NJ. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004, 96(1), 56-67.
  • Calabrese C, Batey M, Thomas HD, Durkacz B, Wang L, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies. Clinical Cancer Research 2003, 9(7), 2711-2718.
  • Thomas HD, Porter D, Bartelink I, Nobbs J, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. British Journal of Clinical Pharmacology 2002, 53(1), 83-91.
  • Koch SSC, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li JK, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. Journal of Medicinal Chemistry 2002, 45(23), 4961-4974.
  • Boddy AV, Griffin MJ, Sludden J, Thomas HD, Fishwick KA, Wright J, Plummer ER, Highley MS, Calvert AH. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemotherapy and Pharmacology 2001, 48(1), 15-21.
  • Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clinical Cancer Research 2001, 7(7), 2105-2113.
  • Marshman, E., Taylor, G., Thomas, H., Newell, D.R., Curtin, N.J. Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole. Biochemical Pharmacology 2001, 61(4), 477-484.
  • Thomas HD, Boddy AV, English M, Hobson R, Imeson J, Lewis I, Morland B, Pearson ADJ, Pinkerton R, Price L, Stevens M, Newell DR. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial. Journal of Clinical Oncology 2000, 18(21), 3614-3621.
  • Thomas HD, Lind M, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemotherapy and Pharmacology 2000, 45(4), 284-290.
  • Boddy AV, Griffin MJ, Wright JG, Sludden JA, Thomas HD, Fishwick K, Plummer R, Highley M, Calvert AH. Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer. British Journal of Cancer 2000, 83(Suppl. 1), 79-79.
  • Calabrese CR, Curtin NJ, Canan-Koch SS, Batey MA, Thomas HD, Kyle S, Wang LZ, Boritzki TJ, Webber SE, Griffin RJ, Golding BT, Hostomsky Z, Calvert AH, Newell DR. Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research 2000, 6(Suppl. 1), 4496 No. 150.
  • Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ. In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121. Clinical Cancer Research 2000, 6(Suppl. 1), 4555S-4555S.
  • Veal GJ, Boddy AV, Thomas HD, Price E, Parry A, Hale J, Pearson ADJ, Dick G, Atra A, Newell DR. Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy. British Journal of Cancer 1999, 80(Suppl. 2), 93-93.
  • Calabrese CR, Thomas HD, Batey MA, Boritzki T, Zhang K, White AW, Curtin NJ, Griffin RJ, Golding BT, Hostomsky Z, Calvert AH, Newell DR. Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research 1999, 5(Suppl. 1), S3839-S3839.
  • Calabrese CR, Thomas HD, Srinivasan S, White AW, Boritzki T, Canon-Koch S, Zhang K. Preclinical pharmacology of novel potent inhibitors of PARP. British Journal of Cancer 1999, 80(supplement 2), 93 P260.
  • Thomas HD, Boddy AV, Pearson ADJ, Pinkerton CR, Lewis I, Stevens M, Imeson J, Hobson R, Newell DR. Validation of pharmacologically-guided dosing of carboplatin in paediatric patients. British Journal of Cancer 1998, 78(Suppl.1), 9-9.
  • Bisogno G, Cowie F, Boddy AV, Thomas HD, Dick G, Pinkerton C. High dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumours. British Journal of Cancer 1998, 77(12), 2304-2309.
  • Siddiqui N, Boddy AV, Thomas HD, Bailey N, Robson L, Lind M, Calvert AH. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. British Journal of Cancer 1997, 75(2), 287-294.
  • Porter D, Boddy AV, Thomas HD, Lind M, Newell DR, Calvert AH, Robson L, Brampton M, Abrahamsen D, Winograd B. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study. Seminars in Oncology 1996, 23(6 supplement 13), 34-44.
  • Mummaneni V, Kaul S, Igwemezie L, Newell DR, Porter D, Thomas HD, Calvert AH, Winograd B, Barbhaiya R. Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters. Journal of Pharmacokinetics and Biopharmaceutics 1996, 24(4), 313-325.
  • Laohavinij S, Wedge S, Lind M, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor G, Thomas HD, Boddy AV, Newell DR, Calvert AH. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Investigational New Drugs 1996, 14(3), 325-335.
  • Calvert AH, Boddy AV, Bailey NP, Siddiqui N, Humphreys A, Hughs A, Robson L, Gumbrell L, Thomas H, Chapman F, Proctor M, Simmons D, Oakey A, Lind MJ, Sinha DV, Newell DR. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Seminars in Oncology 1995, 22(5 Suppl. 12), 91-98.

• Conference Proceedings (inc. Abstracts)

  • Tomassini S, Gentles L, Kirk C, Cross P, Thomas H, Wedge S, Curtin NJ, O'Donnell RL. An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer. In: BASO - The Association for Cancer Surgery Annual Scientific Conference and the NCRI Cancer Conference. 2017, Liverpool: Elsevier.
  • Maegley KA, Bingham P, Tatlock JH, Thomas HD. All PARP inhibitors are not equal: An in vitro mechanistic comparison of PF-01367338 to iniparib. In: JOURNAL OF CLINICAL ONCOLOGY. 2011, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA: AMER SOC CLINICAL ONCOLOGY.
  • Issaeva N, Thomas HD, Pedley N, Djurenovic T, Lundin C, Gubanova E, Sleeth K, Stoimenov I, Chatzakos V, Zdzienicka MZ, Curtin NJ, Helleday T. Exploiting Homologous Recombination Repair Defects in Cancer Cells. In: ENVIRONMENTAL AND MOLECULAR MUTAGENESIS. 2009, DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA: WILEY-LISS.
  • Issaeva N, Thomas HD, Pedley N, Djurenovic T, Lundin C, Gubanova E, Sleeth K, Stoimenov I, Chatzakos V, Zdzienicka MZ, Curtin NJ, Helleday T. Exploiting Homologous recombination repair defects in cancer cells. In: Environmental and Molecular Mutagenesis: Environmental Mutagen Society 40th Annual Meeting, Genomics in the Environmental Society. 2009, St. Louis, Missouri: John Wiley & Sons, Inc.
  • Daniel RA, Rozanska A, Mulligan EA, Drew E, Thomas HD, Castelbuono D, Tweddle DA, Boddy AV, Plummer ER, Hostomsky Z, Curtin NJ, Clifford SC. [abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research. 2009, Denver, CO: American Association for Cancer Research.
  • Williams K, Telfer B, Ali M, Kamjoo M, Thomas H, O'Rourke M, McCrudden C, Hirst D, Curtin NJ. Chemosensitisation by tricyclic poly(ADP-ribose) polymerase (PARP) inhibitors in vivo: More than just DNA repair? [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. 2008, San Diego, California, USA: American Association for Cancer Research.
  • Newell D, Thomas HD, Wang L, Roche C, Bentley J, Cheng Y, Hardcastle I, Golding B, Griffin R, Curtin NJ. [abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. 2008, San Diego, California, USA: American Association for Cancer Research.
  • Clifford S, Daniel R, Rozanska A, Thomas HD, Boddy AV, Tweddle DA, Curtin NJ. Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma. In: 39th International Conference of the International Society for Pediatric Oncology. 2007, National Centre for Performing Arts, Mumbai, India: Pediatric Blood and Cancer.
  • Thomas HD, Calabrese CR, Canan S, Hostomsky ZKS, Maegley K, Newell DR, Skalitzki D, Wang L, Curtin NJ. Identification of a PARP inhibitor for clinical trial: Preclinical studies. In: 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2006, Prague, Czech Republic: European Journal of Cancer Supplements: Pergamon.

• Review

  • Boddy AV, Thomas HD. RMP-7. Potential as an adjuvant to the drug treatment of brain tumours. CNS Drugs 1997, 7(4), 257-263.